Transcode Therapeutics Financials
| RNAZ Stock | USD 0.38 0.04 11.76% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.21 | 1.2764 |
|
|
The essential information of the day-to-day investment outlook for Transcode Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Transcode Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Transcode Therapeutics.
Net Income |
|
Transcode | Select Account or Indicator |
Understanding current and past Transcode Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Transcode Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Transcode Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Transcode Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Transcode Therapeutics. Check Transcode Therapeutics' Beneish M Score to see the likelihood of Transcode Therapeutics' management manipulating its earnings.
Transcode Therapeutics Stock Summary
Transcode Therapeutics competes with Xenetic Biosciences, Reviva Pharmaceuticals, Eyenovia, Cognition Therapeutics, and Kodiak Sciences. TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. The company was incorporated in 2016 and is based in Boston, Massachusetts. Transcode Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US89357L1052 |
| CUSIP | 89357L105 89357L303 89357L204 |
| Location | Massachusetts; U.S.A |
| Business Address | 6 Liberty Square, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.transcodetherapeutics.com |
| Phone | 857 837 3099 |
| Currency | USD - US Dollar |
Transcode Therapeutics Key Financial Ratios
| Return On Equity | -10.49 | ||||
| EBITDA | (17.97 M) | ||||
| Net Income | (18.55 M) | ||||
| Cash Per Share | 1.04 X | ||||
| Current Ratio | 8.06 X |
Transcode Therapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 157.0K | 394.6K | 95.1K | 17.6M | 50.6K | 48.1K | |
| Ebit | (456.9K) | (1.5M) | (6.2M) | (17.6M) | (18.5M) | (17.6M) |
Transcode Therapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Transcode Therapeutics. It measures of how well Transcode is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Transcode Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Transcode had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Transcode Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (8.5K) | 623.5K | 20.0M | (15.9M) | (2.2M) | (2.1M) | |
| Net Income | (607.2K) | (2.3M) | (6.8M) | (17.6M) | (18.5M) | (17.6M) | |
| End Period Cash Flow | 204.5K | 828.0K | 20.8M | 5.0M | 2.8M | 5.5M |
Transcode Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Transcode Therapeutics's current stock value. Our valuation model uses many indicators to compare Transcode Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Transcode Therapeutics competition to find correlations between indicators driving Transcode Therapeutics's intrinsic value. More Info.Transcode Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Transcode Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Transcode Therapeutics' earnings, one of the primary drivers of an investment's value.Transcode Therapeutics Systematic Risk
Transcode Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Transcode Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Transcode Therapeutics correlated with the market. If Beta is less than 0 Transcode Therapeutics generally moves in the opposite direction as compared to the market. If Transcode Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Transcode Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Transcode Therapeutics is generally in the same direction as the market. If Beta > 1 Transcode Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Transcode Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Transcode Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Transcode Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Transcode Therapeutics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Transcode Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Transcode Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Transcode Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Transcode Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Transcode Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.66 | |||
| Information Ratio | 0.0787 | |||
| Maximum Drawdown | 68.8 | |||
| Value At Risk | (11.43) | |||
| Potential Upside | 22.0 |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.